Drug Trial Radar · NCT07893444
BRIGHT-Child TB: Short-Course Treatment for Non-Severe Pulmonary Tuberculosis in Children
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Jul 8, 2026
Primary completion
Nov 30, 2027
Study completion Nov 30, 2028
Sponsor
- Lead sponsor
- Huashan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 3 months, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this Phase II, multicenter, open-label, randomized controlled trial is to evaluate the efficacy and safety of short-course treatment regimens for children with non-severe, drug-susceptible pulmonary tuberculosis. The main questions it aims to answer are: * Do the 3-month bedaquiline, delamanid, contezolid, and pyrazinamide regimen (BDCZ) and the 4-month fixed-dose combination (FDC) regimen provide effective treatment, as measured by tuberculosis-free survival at 12 months after treatment initiation? * What are the safety profiles of the two short-course regimens, as measured by the incidence of grade 3 or higher adverse events? * How do the short-course regimens compare with the standard 6-month treatment regimen in terms of treatment success, treatment failure, recurrence, and tuberculosis-free survival during follow-up? Researchers will compare the 3-month BDCZ regimen and the 4-month FDC regimen with the standard 6-month treatment regimen to evaluate their efficacy and safety in children with non-severe, drug-susceptible pulmonary tuberculosis. Participants will be randomly assigned to one of three treatment groups and will receive the allocated regimen. They will undergo clinical assessments and safety monitoring during treatment, with follow-up to assess treatment outcomes, tuberculosis recurrence, and tuberculosis-free survival at 12, 18, and 24 months after treatment initiation.
Conditions
- Tuberculosis
Interventions
4-month FDC-based regimenDrug
4-month fixed-dose combination (FDC) regimen
3-month BDCZ regimenDrug
3-month bedaquiline, delamanid, contezolid, and pyrazinamide (BDCZ) regimen
Standard 6-month treatment regimenDrug
Standard 6-month treatment regimen, namely 2HRZ(E)/HR.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Tuberculosis-free survival at 12 monthsTime frame: 12 months after treatment initiation
- Incidence of grade 3 or higher adverse eventsTime frame: From treatment initiation to the end of the assigned treatment regimen (3, 4, or 6 months)
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Fuzhou Tuberculosis Prevention and Control Hospital of Fujian Province
Fuzhou, Fujian, China · Recruiting
Guangzhou Chest Hospital
Guangzhou, Guangdong, China · Recruiting
Guiyang Public Health Clinical Center
Guiyang, Guizhou, China · Recruiting
Third People's Hospital of Liupanshui
Liupanshui, Guizhou, China · Recruiting
Zunyi Infectious Diseases Hospital
Zunyi, Guizhou, China · Recruiting
The Fifth People's Hospital of Suzhou
Suzhou, Jiangsu, China · Recruiting
Ganzhou Fifth People's Hospital
Ganzhou, Jiangxi, China · Recruiting
The Fourth People's Hospital of Qinghai Province
Xining, Qinghai, China · Recruiting
Shandong Public Health Clinical Center
Jinan, Shandong, China · Recruiting
Huashan Hospital
Shanghai, Shanghai Municipality, China · Recruiting
The First Affiliated Hospital of Shihezi University
Shihezi, Xinjiang Uygur Autonomous Region, China · Recruiting
Hangzhou Red Cross Hospital
Hangzhou, Zhejiang, China · Recruiting
The Children's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.